CSIMarket Company Name, Ticker, Industry, else..
 
Alpine Immune Sciences Inc   (ALPN)
Other Ticker:  
 
 
Price: $64.9700 $0.01 0.015%
Day's High: $65 Week Perf: 0.03 %
Day's Low: $ 64.97 30 Day Perf: 0.84 %
Volume (M): 4,170 52 Wk High: $ 65.00
Volume (M$): $ 270,902 52 Wk Avg: $28.61
Open: $64.98 52 Wk Low: $8.33



 Market Capitalization (Millions $) 4,160
 Shares Outstanding (Millions) 64
 Employees 36
 Revenues (TTM) (Millions $) 57
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) 19
 Capital Exp. (TTM) (Millions $) 0

Alpine Immune Sciences Inc
Alpine Immune Sciences Inc is a clinical-stage biotechnology company that develops immunotherapies to treat cancer, autoimmune disorders, and other diseases. The company's proprietary technology platform, called Transmembrane Immunomodulatory Protein (TIP) technology, allows the modification and enhancement of various immune system proteins for a more targeted and effective immune response.

The company's pipeline includes several product candidates in various stages of development. ALPN-101, the company's lead product candidate, is a dual ICOS/CD28 antagonist designed to treat autoimmune and inflammatory diseases. The drug is currently in Phase 2 clinical trials for patients with systemic lupus erythematosus (SLE), and additional trials are planned for rheumatoid arthritis, psoriasis, and other indications.

Another product candidate, ALPN-202, is a bi-functional fusion protein that targets both PD-L1 and CTLA-4 in the tumor microenvironment. This product candidate is being developed for the treatment of solid tumors and is currently in preclinical development.

Alpine Immune Sciences also has collaborations with several companies, including AbbVie, Bristol Myers Squibb, and Kite, a Gilead Company, to develop innovative immunotherapies.

The company was founded in 2015 and is headquartered in Seattle, Washington. It became a public company in 2017 and is traded on the NASDAQ under the ticker symbol ALPN. It has a market capitalization of approximately $172 million as of June 202 The company has a dedicated team of experienced professionals, including scientists and industry veterans, who are committed to developing innovative immunotherapies to improve the lives of patients.


   Company Address: 188 East Blaine Street, Suite 200 Seattle 98102 WA
   Company Phone Number: 788-4545   Stock Exchange / Ticker: NASDAQ ALPN


Customers Net Income grew by ALPN's Customers Net Profit Margin grew to

75.89 %
14.87 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMAT        6.15% 
APH        4.69% 
GLW        3.73% 
KLAC        5.86% 
LRCX        4.82% 
TEL        0.7% 
• View Complete Report
   



Alpine Immune Sciences Inc

Examination of Financial Performance Reveals a Loss of $-0.28 per Share in Q1 2024 for Alpine Immune Sciences Inc

Alpine Immune Sciences, a leading clinical-stage immunotherapy company, has recently presented encouraging translational data on two of their innovative treatments for autoimmune and inflammatory diseases. The presentations focused on povetacicept (ALPN-303) and acazicolcept (ALPN-101), highlighting their potential in the treatment of systemic lupus erythematosus (SLE) and autoimmune glomerulonephritis.
At the SLEuro 14th European Lupus Meeting in Bruges, Belgium, Alpine Immune Sciences shared compelling translational data on povetacicept. The data revealed a significant increase in gene expressions related to B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) in myeloid and B cells of patients with systemic lupus erythematosus. This finding suggests that povetacicept may hold promise as a potential therapeutic option for this debilitating autoimmune disease.
Product Service News

Alpine Immune Sciences Unveils Exciting Breakthroughs in Lupus and Glomerulonephritis Treatment with Povetacicept and Acazicolcept

Published Thu, Mar 21 2024 11:45 AM UTC

Alpine Immune Sciences Presents Promising Translational Data on Povetacicept and Acazicolcept for the Treatment of Lupus and Glomerulonephritis Alpine Immune Sciences, a leading clinical-stage immunotherapy company, recently presented new translational data on two of their innovative treatments for autoimmune and inflammatory diseases at prestigious medical conferences. The ...
Alpine Immune Sciences Inc

2 Analyzing the Factors Behind Alpine Immune Sciences Inc's Surge in Earnings

Alpine Immune Sciences Inc (ALPN) has seen a significant increase in its share value over the past three months, with a 110.53% growth rate. However, the month of March saw a slight dip of 1.06% in ALPN shares. Despite this, the company remains just 7.4% short of its 52-week high. This upward trend in share value is reflective of the positive financial performance and strategic partnerships that Alpine Immune Sciences has recently secured.
In its fiscal fourth quarter of 2023, Alpine Immune Sciences reported a remarkable revenue advance of 1011.419% year-on-year, reaching $30.85 million. This impressive growth led to a turnaround in profitability, with the company presenting an income per share of $0.08. This is a significant improvement from the previous reporting season, where income per share was at $-0.24. Additionally, revenue doubled by 207.209% from $10.04 million in the same period.
Business Update

Alpine Immune Sciences Strengthens Partnership with AbbVie and Achieves Impressive Revenue Growth Amidst Pandemic Challenges

Published Thu, Dec 21 2023 9:15 PM UTC

Alpine Immune Sciences Updates License Agreement with AbbVie and Demonstrates Revenue GrowthSeattle-based immunotherapy company, Alpine Immune Sciences, has announced an amendment to its option and license agreement with AbbVie, a global biopharmaceutical company. The agreement focuses on the development of acazicolcept, an innovative treatment for autoimmune and inflammator...
Product Service News

Alpine Immune Sciences' Breakthrough Therapy for Systemic Lupus Erythematosus Shines at ACR Convergence 2023, Fueling Remarkable Revenue Growth

Published Wed, Nov 15 2023 2:00 PM UTC

Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus and Reports Strong Revenue Growth
Alpine Immune Sciences, a renowned clinical-stage immunotherapy company specializing in innovative treatments for autoimmune and inflammatory diseases, recently presented new translational data for povetacicept (ALPN-303) in systemic lu...






Alpine Immune Sciences Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com